Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Eli Lilly, Food and Drug Administration
Eli Lilly’s weight-loss drug no longer in shortage, FDA says
The two-year shortage of Eli Lilly’s blockbuster weight-loss and diabetes drugs is over, the U.S. Food and Drug Administration announced Wednesday.
Eli Lilly’s Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers.
Blockbuster drugs Zepbound and Mounjaro have come off the FDA's shortage list. Shares of Hims & Hers, which had capitalized on the pinch, are tumbling.
What end of Eli Lilly's weight-loss drug shortage means for the competition
The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 diabetes drug Mounjaro, implying the company can now supply enough doses to meet current demand.
Eli Lilly’s Weight-Loss, Diabetes Drug Shortages Are Over, FDA Says
The removal of Zepbound and Mounjaro from the regulator’s shortage list could lead to restrictions on pharmacies making custom-made versions.
Hims & Hers Health stock tanks after FDA says competitor Eli Lilly’s weight-loss drug shortage is over
The San Francisco telehealth company had capitalized on the shortage by making copycat versions of popular brand-name GLP-1 medications.
Eli Lilly’s Weight-Loss Drugs No Longer In Shortage. It’s Bad News for These Stocks.
Eli Lilly’s blockbuster obesity and diabetes drugs Zepbound and Mounjaro are no longer in shortage, according to the Food and Drug Administration. It’s a sign that the pharmaceutical giant is making strides to improve the supply issues that have plagued the sector.
4d
on MSN
Eli Lilly plans $4.5 billion facility in LEAP District, bringing investment to $13 billion
The $4.5 billion investment will create the Lilly Medicine Foundry, a center that will combine research and manufacturing ...
5d
on MSN
Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...
FierceBiotech
3h
AstraZeneca pays CSPC $100M for preclinical heart disease drug, teeing up combos and Lilly rivalry
AstraZeneca has paid CSPC Pharmaceutical Group $100 million for a preclinical cardiovascular disease drug candidate. The deal ...
4d
on MSN
Drugmaker Lilly slates another $4.5B for manufacturing and drug development improvements
Lilly will add the center to a site in Lebanon, Indiana, where it is already spending about $9 billion to improve ...
2d
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...
FiercePharma
5d
High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project
As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of ...
4d
Eli Lilly’s weight-loss and diabetes drugs are no longer in shortage, says FDA
The U.S. Food and Drug Administration said Eli Lilly’s diabetes and weight-loss drugs marketed as Zepbound and Mounjaro are ...
2h
on MSN
Eli Lilly and Company (LLY): Hedge Funds Are Bullish On This Momentum Stock Now
We recently compiled a list of the 8 Best Momentum Stocks To Invest In Right Now. In this article, we are going to take a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Mounjaro
Zepbound
Feedback